Duration of Prophylactic Levetiracetam After Surgery for Brain Tumor: A Prospective Randomized Trial
Authors:
- 26 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 92 (1) , 68-74
Abstract
BACKGROUND: Levetiracetam is commonly used as a prophylactic antiseizure medication in patients undergoing surgical resection of brain tumors. OBJECTIVE: To quantitate side effects experienced in patients treated with 1 week vs 6 weeks of prophylactic levetiracetam using validated measures for neurotoxicity and depression. METHODS: Patients undergoing surgical resection of a supratentorial tumor with no seizure history were randomized within 48 hours of surgery to receive prophylactic levetiracetam for the duration of either 1 or 6 weeks. Patients were given oral levetiracetam extended release 1000 mg during the first part of this study. Owing to drug backorder, patients enrolled later in this study received levetiracetam 500 mg BID. The primary outcome was the change in the neurotoxicity score 6 weeks after drug initiation. The secondary outcome was seizure incidence. RESULTS: A total of 81 patients were enrolled and randomized to 1 week (40 patients) or 6 weeks (41 patients) of prophylactic levetiracetam treatment. The neurotoxicity score slightly improved in the overall cohort between baseline and reassessment. There was no significant difference between groups in neurotoxicity or depression scores. Seizure incidence was low in the entire cohort of patients with 1 patient in each arm experiencing a seizure during the follow-up period. CONCLUSION: The use of prophylactic levetiracetam did not result in significant neurotoxicity or depression when given for either 1 week or 6 weeks. The incidence of seizure after craniotomy for tumor resection is low regardless of duration of therapy.Keywords
This publication has 22 references indexed in Scilit:
- A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumorsJournal of Neurosurgery, 2013
- The Role of Levetiracetam in Treatment of Seizures in Brain Tumor PatientsFrontiers in Neurology, 2013
- A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomasNeurology India, 2013
- Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgeryJournal of Neuro-Oncology, 2010
- Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: An indirect comparison of treatment-emergent adverse events using meta-analytic techniquesEpilepsy & Behavior, 2009
- Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experienceJournal of Neuro-Oncology, 2009
- Results of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain TumorsJournal of Neuro-Oncology, 2005
- Prophylactic Antiepileptic Drugs in Patients with Brain TumorsEpilepsy Currents, 2005
- Safety Profile of LevetiracetamEpilepsia, 2001
- The Neurotoxicity Scale: The validity of a patient-based scale, assessing neurotoxicityEpilepsy Research, 1995